文献速递白血病

急性髓系白血病:2021年风险分层与管理更新

Acute myeloid leukemia: 2021 update on risk-stratification and management.
PubMed 文献 · Am J Hematol · 2020-01-01

该综述讨论急性髓系白血病(AML)管理中选择姑息治疗、标准治疗或研究性治疗(临床试验)的决策,基于随机试验指出CPX-351、米哚妥林、吉妥珠单抗奥唑米星和维奈克拉(后三者联合其他药物)应被视为标准治疗,并强调预后算法、可测量残留病及异基因移植的获益/风险比。

要点

  • 大多数老年AML患者可能从治疗中获益,管理需在姑息治疗、标准治疗和研究性治疗间选择。
  • 基于随机试验,CPX-351、米哚妥林、吉妥珠单抗奥唑米星和维奈克拉(后三者联合其他药物)应被视为标准治疗。
  • 医生接诊新诊断患者时须决定提供常规治疗还是研究性治疗,后者最好在临床试验背景下进行。

核心结论

  • 基于随机试验,CPX-351、米哚妥林、吉妥珠单抗奥唑米星和维奈克拉(后三者联合其他药物)应被视为标准治疗。
  • 了解这些疗法的可能结果对于决定是否推荐它们或参与临床试验(可能包括这些药物)至关重要。
  • 医生接诊新诊断患者时必须决定提供常规治疗还是研究性治疗,后者最好在临床试验背景下进行。
  • 在老年患者中,决策常包括询问是否应提供特异性抗AML治疗,而非仅关注以输血和抗生素支持为重点的纯姑息治疗并涉及姑息治疗专家。

研究设计与样本

  • 综述,在已建立的预后算法背景下,比较近期获批药物与其前代药物的结果并描述其他潜在选择。
  • 讨论提供异基因移植决策背后的获益/风险比,并强调可测量残留病的重要性。

主要发现

  • 基于随机试验CPX-351、米哚妥林、吉妥珠单抗奥唑米星和维奈克拉(后三者联合其他药物)应被视为标准治疗。
  • 与甚至1-2年前相比,临床试验已导致当今被视为「常规」治疗的变化。

临床怎么用

  • 医生接诊新诊断患者时必须决定提供常规治疗还是研究性治疗,后者最好在临床试验背景下进行。
  • 在老年患者中,决策常包括询问是否应提供特异性抗AML治疗,而非仅关注纯姑息治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Management of AML involves choosing between purely palliative care, standard therapy and investigational therapy ("clinical trial"). Even most older patients likely benefit from treatment. Based on randomized trials CPX 351, midostaurin, gemtuzumab ozogamicin, and venetoclax, the latter three when combined with other drugs, should now be considered standard therapy. Knowledge of the likely results with these therapies is essential in deciding whether to recommend them or participate in a clinical trial, possibly including these drugs. Hence here, in the context of established prognostic algorithms, we review results with the recently- approved drugs compared with their predecessors and describe other potential options. We discuss benefit/risk ratios underlying the decision to offer allogeneic transplant and emphasize the importance of measurable residual disease. When first seeing a newly-diagnosed patient physicians must decide whether to offer conventional treatment or investigational therapy, the latter preferably in the context of a clinical trial. As noted below, such trials have led to changes in what today is considered "conventional" therapy compared to even 1-2 years ago. In older patients decision making has often included inquiring whether specific anti-AML therapy should be offered at all, rather than focusing on a purely palliative approach emphasizing transfusion and antibiotic support, with involvement of a palliative care specialist.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Estey EH. Acute myeloid leukemia: 2021 update on risk-stratification and management. Am J Hematol. 2020. PMID: 32833263. doi:10.1002/ajh.25975

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。